InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
The Watchlist
Previous Video
Next Video
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online